{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:00:49Z","timestamp":1790647249442,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1136\/ijgc-2023-004860","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T06:25:13Z","timestamp":1717827913000},"page":"1001-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Alexandra","family":"Diggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeh","family":"Szamreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Joseph","family":"Monberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-825X","authenticated-orcid":false,"given":"Jason D","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004860_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA3","article-title":"Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)","volume":"39","author":"Mileshkin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0015","unstructured":"National Comprehensive Cancer Network . Cervical cancer (version 1.2022). n.d.Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf"},{"key":"10.1136\/ijgc-2023-004860_bb0020","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004860_bb0025","author":"IARC","year":"2021","journal-title":"GLOBOCAN 2020, cancer incidence and mortality worldwide"},{"key":"10.1136\/ijgc-2023-004860_bb0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajog.2009.06.015","article-title":"Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation","volume":"201","author":"Bansal","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004860_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","article-title":"Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer","volume":"350","author":"Landoni","year":"1997","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004860_bb0040","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/COC.0b013e3181cae5b7","article-title":"Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study","volume":"33","author":"Yamashita","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2004.04.016","article-title":"Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy","volume":"94","author":"Yessaian","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0055","unstructured":"National Cancer Institute . Surveillance, epidemiology and end results program. n.d.Available: https:\/\/seer.cancer.gov\/"},{"key":"10.1136\/ijgc-2023-004860_bb0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0002-9378(16)32742-9","article-title":"Site of recurrence of cervical cancer after radical hysterectomy","volume":"138","author":"Webb","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004860_bb0065","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.suronc.2011.12.008","article-title":"Management of recurrent cervical cancer: a review of the literature","volume":"21","author":"Peiretti","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0070","author":"Hansen","year":"2017","journal-title":"The Truven health MarketScan databases for life sciences researchers"},{"key":"10.1136\/ijgc-2023-004860_bb0075","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MLR.0000000000000735","article-title":"Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser comorbidity index","volume":"55","author":"Moore","year":"2017","journal-title":"Med Care"},{"key":"10.1136\/ijgc-2023-004860_bb0080","article-title":"Management of recurrent or metastatic cervical cancer","author":"Wright","year":"2022","journal-title":"UptoDate"},{"key":"10.1136\/ijgc-2023-004860_bb0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2018.06.023","article-title":"Twenty-first century cervical cancer management: a historical perspective of the gynecologic oncology group\/NRG oncology over the past twenty years","volume":"150","author":"Leath","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0090","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0095","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.6004\/jnccn.2008.0006","article-title":"Chemotherapy for advanced, recurrent, and metastatic cervical cancer","volume":"6","author":"Moore","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004860_bb0105","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2023.01.010","article-title":"Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: an NRG oncology randomized study","volume":"171","author":"Tewari","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0120","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004860_bb0125","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004860_bb0130","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0135","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004860_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004860_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2009.09.006","article-title":"Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0150","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2006.09.3781","article-title":"Management of metastatic cervical cancer: review of the literature","volume":"25","author":"Long","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004860_bb0155","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1002\/cncr.24364","article-title":"Novel chemotherapy approaches for cervical cancer","volume":"115","author":"Movva","year":"2009","journal-title":"Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:57:05Z","timestamp":1762354625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1048891X25009259"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004860","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}